journal
https://read.qxmd.com/read/39242322/physical-compatibility-of-reduced-glutathione-for-injection-with-44-intravenous-drugs-during-simulated-y-site-administration
#1
JOURNAL ARTICLE
Rui Wu, Gaochao Zhu, Yinghui Ju, Yue Zhu, Menglin Wang, Yangyu Zhao, Sheng Liu
PURPOSE: Reduced glutathione (GSH) is extensively used in clinical therapeutics due to its antioxidative and cytoprotective properties. It is essential in the management of various chronic and acute conditions and serves as an adjunct therapy in oncology. Despite its widespread use, the physical compatibility of GSH with other intravenous drugs during Y-site administration has not been thoroughly investigated, posing risks such as reduced efficacy and adverse reactions. This study fills this critical gap by examining the physical compatibility of GSH with 44 commonly used intravenous drugs in simulated Y-site administration with 0...
September 5, 2024: Clinical Therapeutics
https://read.qxmd.com/read/39218705/the-landscape-of-blood-based-screening-assays-after-the-fallacy-of-theranos-inc
#2
EDITORIAL
Jill L Maron
No abstract text is available yet for this article.
August 31, 2024: Clinical Therapeutics
https://read.qxmd.com/read/39214713/the-effect-of-rituximab-on-the-cognitive-function-of-patients-with-relapsing-remitting-multiple-sclerosis
#3
JOURNAL ARTICLE
Masood Najafi, Ghasem Farahmand, Pargol Balali, Atefeh Behkar, Mojtaba Shahbazi, Negar Moradian, Sara Pouyanmanouchehri, Mohammad Hossein Harirchian, Sara Ranji
PURPOSE: Cognitive impairment can begin in the early stages of multiple sclerosis (MS). No medicine has been approved for treating cognitive impairment in MS patients. There is a lack of data on the role of rituximab in managing cognitive impairment in MS patients. Using minimal assessment of cognitive function in MS (MACFIMS), this study aims to investigate the effect of rituximab on the cognitive status of relapsing-remitting MS (RRMS) patients. METHODS: In this pre-post interventional trial, 28 eligible RRMS patients participated...
August 29, 2024: Clinical Therapeutics
https://read.qxmd.com/read/39183124/combination-of-high-dose-daptomycin-and-ceftriaxone-for-cardiac-implantable-electronic-device-infections-a-10-year-experience
#4
JOURNAL ARTICLE
Giacomo Ponta, Martina Ranzenigo, Alessandra Marzi, Chiara Oltolini, Chiara Tassan Din, Caterina Uberti-Foppa, Vincenzo Spagnuolo, Patrizio Mazzone, Paolo Della Bella, Paolo Scarpellini, Antonella Castagna, Marco Ripa
PURPOSE: Cardiac implantable electronic device (CIED) infections are increasingly common. Gram-positive bacteria such as coagulase negative staphylococci and Staphylococcus aureus are the most commonly involved pathogens. The aim of this study was to describe the characteristics and outcome of patients with CIED infections who underwent device removal and were empirically treated with high dose (8-12 mg/kg daily) daptomycin (DAP) in combination with ceftriaxone (CRO). METHODS: Retrospective, single center study including patients admitted at IRCCS San Raffaele Hospital (Milan, Italy), from June 2011 to June 2021, who underwent device removal for CIED infection and were empirically treated with DAP/CRO...
August 24, 2024: Clinical Therapeutics
https://read.qxmd.com/read/39181829/effect-of-raloxifene-treatment-on-apolipoproteins-and-lipoprotein-a-concentrations-in-postmenopausal-women-a-meta-analysis-of-randomized-controlled-trials
#5
REVIEW
Xinyi Liao, Jian Deng, Lei Du, Benjamin Hernández-Wolters, Kousalya Prabahar, Hamed Kord-Varkaneh
BACKGROUND AND AIM: Although various randomized controlled trials (RCTs) have evaluated the effect of raloxifene on apolipoproteins and lipoprotein(a) concentrations in postmenopausal women, the results have been inconsistent and inconclusive. Therefore, we conducted this meta-analysis of RCTs to investigate the effect of raloxifene administration on apolipoproteins and lipoprotein(a) [Lp(a)] concentrations in postmenopausal women. METHODS: Two independent researchers systematically searched the scientific literature (including PubMed/Medline, Scopus, Web of Science, and EMBASE) for English-language randomized controlled trials (RCTs) published up to June 2024...
August 23, 2024: Clinical Therapeutics
https://read.qxmd.com/read/39179458/racial-comparison-of-the-pharmacokinetics-and-safety-of-fixed-dose-combination-of-dapagliflozin-sitagliptin-in-western-and-korean-healthy-adults
#6
JOURNAL ARTICLE
Pradeep B Lukka, Weifeng Tang, Ann Hammarstedt, Tom Conrad, Maria Heijer, Cecilia Karlsson, David W Boulton
PURPOSE: We evaluated the pharmacokinetics, safety, and tolerability of a fixed-dose combination (FDC) of dapagliflozin/sitagliptin versus individual component (IC) tablets in healthy Western and Korean participants. The combination of these antihyperglycemic drugs provides efficient glucose control, and the use of FDC has generally been shown to improve medication adherence in individuals with type 2 diabetes mellitus (T2DM). METHODS: Two randomized, open-label, two-period, two-treatment, single-dose, single-center, crossover bioequivalence studies conducted on healthy fasted German participants (aged 18-55 years; Western study) and South Korean participants (aged 19-55 years; Korean study) were included...
August 22, 2024: Clinical Therapeutics
https://read.qxmd.com/read/39155175/cost-effectiveness-of-azvudine-for-high-risk-outpatients-with-mild-to-moderate-coronavirus-disease-2019-in-china
#7
JOURNAL ARTICLE
Hui Yang, Zhaojian Wang, Chunping Wang, Ying Zhang, Sheng Han, Zhuoling An
PURPOSE: This study aimed to evaluate the cost-effectiveness of Azvudine for the treatment of mild-to-moderate coronavirus disease 2019 in high-risk outpatients using real-world data and relevant references. METHODS: In the decision-tree model, 2 cohorts were organized in a single center to compare the cost-effectiveness between the Azvudine plus symptomatic treatment group and the symptomatic treatment group. We calculated the cost and mortality rate for both groups...
August 17, 2024: Clinical Therapeutics
https://read.qxmd.com/read/39153912/aspirin-and-ticagrelor-versus-aspirin-and-clopidogrel-or-pasugrel-and-the-effect-on-staphylococcal-associated-infections-a-real-world-study
#8
JOURNAL ARTICLE
Hani Essa, Wern Yew Ding, Faraz Rana, Sizheng Steven Zhao, Matthew Anson, Philip Austin, Gema Hernández, Pankaj Lal, Gregory Y H Lip, Uazman Alam
PURPOSE: Antiplatelet therapy is used for the primary and secondary prevention of thrombotic diseases such as acute coronary syndrome (ACS). These patients are more vulnerable to infections, as such, strategies are required to mitigate these risks. METHODS: We conducted a retrospective cohort study using TriNetX, a global federated health research network that includes both inpatient and outpatient electronic medical records from health care organizations worldwide...
August 16, 2024: Clinical Therapeutics
https://read.qxmd.com/read/39153911/weight-loss-with-once-nightly-sodium-oxybate-for-the-treatment-of-narcolepsy-analysis-from-the-phase-iii-randomized-study-evaluating-the-efficacy-and-safety-of-a-once-nightly-formulation-of-sodium-oxybate-rest-on-trial
#9
JOURNAL ARTICLE
Thomas Roth, Anne Marie Morse, Richard Bogan, Asim Roy, Jennifer Gudeman, Yves Dauvilliers
PURPOSE: Individuals with narcolepsy are more likely to be obese than the general population. Changes in weight-related measures with extended-release, once-nightly sodium oxybate (ON-SXB) and characteristics of participants with ≥5% weight loss were assessed in a Randomized study Evaluating the efficacy and SafeTy of a ONce nightly formulation of sodium oxybate (REST-ON) trial post hoc analysis. METHODS: REST-ON (NCT02720744) was a Phase III, double-blind, placebo-controlled, multicenter, randomized clinical trial...
August 16, 2024: Clinical Therapeutics
https://read.qxmd.com/read/39153910/longitudinal-vasoactive-inotrope-score-trajectories-and-their-prognostic-significance-in-critically-ill-sepsis-patients-a-retrospective-cohort-analysis
#10
JOURNAL ARTICLE
Shiji Xiao, Qiufeng Zhuang, Yinling Li, Zhibin Xue
PURPOSE: Sepsis continues to be a critical issue in intensive care, characterized by significant morbidity and mortality. This study explores the association between Vasoactive Inotrope Score (VIS) trajectories and 28-day mortality in ICU patients with sepsis, employing VIS trajectories as a marker for assessing severity and guiding therapy. METHODS: We conducted a retrospective analysis of the MIMIC-IV database, which included sepsis patients admitted to the ICU between 2008 and 2019...
August 16, 2024: Clinical Therapeutics
https://read.qxmd.com/read/39142926/pharmacokinetics-safety-tolerability-and-exploratory-efficacy-of-upadacitinib-in-children-with-severe-atopic-dermatitis
#11
JOURNAL ARTICLE
Yuli Qian, Eliza M Raymundo, Shuai Hao, Kristina Unnebrink, Gweneth F Levy, Henrique D Teixeira, Alvina D Chu, Zachary A Zinn, Amy S Paller, Wei Liu, Mohamed-Eslam F Mohamed
PURPOSE: This study aims to characterize the pharmacokinetics, safety, tolerability, and exploratory efficacy of upadacitinib, an oral Janus kinase inhibitor approved for treating moderate to severe atopic dermatitis (AD) in adults and adolescents, in children with severe AD. METHODS: In an open-label, multiple-dose, Phase 1 study, pediatric patients with severe AD from two age groups (2 to <6 years and 6 to <12 years) received bodyweight-based dosing regimens of upadacitinib using either twice-daily immediate-release (IR) oral solution or once-daily extended-release (ER) tablets...
August 13, 2024: Clinical Therapeutics
https://read.qxmd.com/read/39142925/current-approaches-in-postapproval-vaccine-safety-studies-using-real-world-data-a-systematic-review-of-published-literature
#12
REVIEW
Juan Joanne Wu, Manfred Hauben, Muhammad Younus
PURPOSE: Well-designed observational postmarketing studies using real-world data (RWD) are critical in supporting an evidence base and bolstering public confidence in vaccine safety. This systematic review presents current research methodologies in vaccine safety research in postapproval settings, technological advancements contributing to research resources and capabilities, and their major strengths and limitations. METHODS: A comprehensive search was conducted using PubMed to identify relevant articles published from January 1, 2019, to December 31, 2022...
August 13, 2024: Clinical Therapeutics
https://read.qxmd.com/read/39117488/a-phase-i-dose-escalation-study-of-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-polyethylene-glycol-erythropoietin-peg-epo-in-healthy-subjects
#13
JOURNAL ARTICLE
Chaoying Hu, Wanling Sun, Yuanyuan Wu, Junlong Huang, Xiangrong Zhang, Lan Zhang
PURPOSE: This first-in-human trial aimed to investigate the pharmacokinetics and pharmacodynamics characteristics and safety and tolerability of single ascending doses of subcutaneous polyethylene glycol-erythropoietin (PEG-EPO) in healthy subjects. METHODS: In this phase I, randomized, double-blind, placebo-controlled, dose-escalating trial, subjects were sequentially enrolled into 7 cohorts with 12 subjects in each cohort and randomized in a 5:1 ratio to receive a single dose of 0...
August 7, 2024: Clinical Therapeutics
https://read.qxmd.com/read/39117487/the-predictive-potential-of-c-peptide-in-differentiating-type-1-diabetes-from-type-2-diabetes-in-an-outpatient-population-in-abu-dhabi
#14
JOURNAL ARTICLE
Sajid Iqbal, Abdulrahim Abu Jayyab, Ayah Mohammad Alrashdi, Syed Shujauddin, Josep Lluis Clua-Espuny, Silvia Reverté-Villarroya
PURPOSE: We aimed to investigate the predictive potential of plasma connecting peptide (C-peptide) in differentiating type 1 diabetes (T1D) from type 2 diabetes (T2D) and to inform evidence-based diabetes classification criteria. METHODS: A retrospective review was performed of all the patients with diabetes visiting an outpatient diabetology, endocrinology, general practice and family medicine tertiary health care center between January 2016 and December 2021. FINDINGS: Two hundred twelve individuals with diabetes were included, 85 (44...
August 7, 2024: Clinical Therapeutics
https://read.qxmd.com/read/39112102/harmonize-asia-a-phase-iii-randomized-study-to-investigate-the-efficacy-and-safety-of-sodium-zirconium-cyclosilicate-in-patients-with-hyperkalemia-in-china
#15
JOURNAL ARTICLE
Xinling Liang, Wanhong Lu, Xueqing Yu, Hong Cheng, Qiang He, Qingfeng Peng, Zhaohui Ni, Gang Long, Lihua Wang, Wei Chen, Rong Li, June Zhao, Yong Zhang, Vera Lisovskaja, Zhiji Tang
PURPOSE: Sodium zirconium cyclosilicate (SZC) is an oral potassium (K+ )-lowering therapy for adults with hyperkalemia. HARMONIZE Asia (ClinicalTrials.gov identifier: NCT03528681) evaluated the efficacy and safety of SZC in Chinese patients with hyperkalemia. METHODS: This Phase III, randomized, double-blind, placebo-controlled study recruited patients with serum K+ (sK+ ) ≥5.1 mmol/L at 35 sites in China. Patients received SZC 10 g three times daily (TID) for 24 or 48 hours during an open-label initial phase (OLP)...
August 6, 2024: Clinical Therapeutics
https://read.qxmd.com/read/39107168/artificial-intelligence-drug-development-and-frameworks-an-opportunity-to-enhance-understanding
#16
EDITORIAL
Paul Beninger
No abstract text is available yet for this article.
August 5, 2024: Clinical Therapeutics
https://read.qxmd.com/read/39097520/effects-of-propolis-consumption-on-glycemic-indices-and-liver-enzymes-in-adults-a-grading-of-recommendations-assessment-development-and-valuation-assessed-systematic-review-and-dose-response-meta-analysis
#17
REVIEW
Shaghayegh Adeli, Mahsa Maroofi, Fatemeh Pourteymour Fard Tabrizi, Beitullah Alipour, Marzieh Heidari, Mahdi Vajdi, Mahdieh Abbasalizad-Farhangi
PURPOSE: Even though various randomized controlled trials (RCTs) have assessed the effect of propolis on glycemic indices and liver enzyme concentrations in adults, results have been inconsistent, without conclusive evidence. This systematic review and meta-analysis of RCTs sought to evaluate the effects of propolis consumption on glycemic indices and liver enzymes, fasting blood glucose, insulin, homeostatic model assessment of insulin resistance, glycosylated hemoglobin, alanine transaminase, aspartate aminotransferase, and gamma-glutamyl transferase in adults...
August 2, 2024: Clinical Therapeutics
https://read.qxmd.com/read/39089982/cost-effectiveness-analysis-of-comt-inhibitors-as-adjuvant-treatments-to-levodopa-in-patients-with-advanced-parkinson-s-disease
#18
JOURNAL ARTICLE
Nayoung Kwak, Hye-Young Kang, Myung-Jun Lee, Hankil Lee
PURPOSE: We aimed to elicit scientific evidence on the cost-effectiveness of two catechol-O-methyltransferase inhibitors (COMT-i) versus no COMT-i in patients with advanced Parkinson's disease. METHODS: A mixed model of the decision tree and a Markov model with three health states by OFF-time level (<25%, ≥25%, and death) was constructed to compare opicapone (OPC), entacapone (ENT), and no COMT-i over a lifetime. A hypothetical cohort of 10,000 patients was created and simulated based on the characteristics of the BIPARK trial subjects...
July 31, 2024: Clinical Therapeutics
https://read.qxmd.com/read/39084911/pancreatitis-and-pancreatic-cancer-risk-among-patients-with-type-2-diabetes-receiving-dipeptidyl-peptidase-4-inhibitors-an-updated-meta-analysis-of-randomized-controlled-trials
#19
REVIEW
Adili Tuersun, Guanxin Hou, Gang Cheng
PURPOSE: This meta-analysis sought to assess the relationship between dipeptidyl peptidase-4 inhibitors (DPP-4) and the risk of pancreatitis and pancreatic cancer by synthesizing data from randomized, controlled trials, in light of the conflicting findings from observational studies and previous meta-analyses. METHODS: Cochrane, Embase, ClinicalTrials.gov, and PubMed databases that compared the use of DPP-4 inhibitors and that reported pancreatitis and pancreatic cancer events in patients with diabetes mellitus Type 2 (T2DM) were searched using specific terms...
July 30, 2024: Clinical Therapeutics
https://read.qxmd.com/read/39069432/one-year-efficacy-and-safety-of-dulaglutide-in-patients-with-type-2-diabetes-and-chronic-kidney-disease-a-retrospective-study-of-asian-patients
#20
JOURNAL ARTICLE
Myung Jin Kim, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee
PURPOSE: Dulaglutide is a long-acting glucagon-like peptide-1 receptor agonist that is not cleared by the kidneys and has proven efficacy and safety in patients with diabetic kidney disease. We aimed to evaluate the 1-year efficacy of dulaglutide in patients with diabetic kidney disease who have used the drug for more than 1 year. METHODS: This retrospective, observational study comprised 131 patients with an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1...
July 27, 2024: Clinical Therapeutics
journal
journal
27126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.